Home > Boards > US Listed > Medical - Drugs > VYNE Therapeutics (VYNE)

$MNLO looking at $250 million-plus in peak sales

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
BiotechValues Member Profile
 
Followed By 340
Posts 10,238
Boards Moderated 2
Alias Born 06/23/07
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/2/2021 5:09:22 PM
LifeSci Capital Thinks VYNE Therapeutics’ Stock is Going to Recover TipRanks - 11/22/2021 4:04:52 AM
VYNE Therapeutics EPS misses by $0.04, misses on revenue Seeking Alpha - 11/10/2021 7:36:34 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/10/2021 7:31:58 AM
VYNE Therapeutics Q3 2021 Earnings Preview Seeking Alpha - 11/9/2021 11:53:01 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2021 8:36:51 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/26/2021 8:16:43 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/1/2021 5:14:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/1/2021 5:13:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2021 5:35:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2021 5:35:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2021 5:34:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/3/2021 5:16:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/26/2021 5:05:22 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 8/25/2021 5:05:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/18/2021 7:20:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2021 4:47:14 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/12/2021 5:11:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/12/2021 5:07:47 PM
NanoVibronix, Apyx Medical leads healthcare gainers; MedAvail, LifeStance Health among major losers Seeking Alpha - 8/12/2021 11:05:26 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/12/2021 8:37:28 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2021 4:34:10 PM
VYNE Therapeutics' Amzeeq and Zilxi approved in Chinese economic pilot zone Seeking Alpha - 8/2/2021 8:49:58 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/20/2021 5:07:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/20/2021 5:07:03 PM
BiotechValues   Sunday, 04/26/20 10:26:11 AM
Re: None
Post # of 734 
$MNLO looking at $250 million-plus in peak sales per Cowen in this article out today. Don't believe this includes any potential sales in China from last week's pr.

“…our clinicians continue to highlight their even greater enthusiasm for FMX-103, given that rosacea – although a smaller overall market than acne – has very limited treatment options. Taking the likely lower penetration of Amzeeq into the massive acne market, combined with the likely high penetration of FMX-103 into the smaller rosacea market, we continue to believe that these opportunities could eventually each exceed $250 million-plus in peak sales, which is clearly not reflected in the current valuation.”


“the launch was progressing as well as – and if not better – than any recent launch in acne.” Total prescriptions hit the 2,150 mark for the week ending March 13, indicating a revenue run-rate of about $20-$25 million.


https://blog.tipranks.com/3-biotech-stocks-under-4-with-big-upside-potential/

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences